FDA grants approval of pralsetinib (Gavreto) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer

Approval of pralsetinib, a once-daily oral RET-targeted therapy, was based on the phase 1/2 ARROW trial, which showed efficacy in patients with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement.


Biospace Inc.